Month: May 2025

In accordance with the voting results of the closed-end investment company intended for informed investors UAB “Atsinaujinančios energetikos investicijos” (hereinafter − the Company) at the extraordinary general meeting of shareholders held on 16 May 2025, the shareholders of the Company approved the extension of the Company’s term of operation by an additional two years, with more than a 9/10 majority of votes cast by all the shares held by the Company’s shareholders. As a result, the Company’s term of operation is considered extended until 5 February 2028. Contact person for further information: Mantas Auruškevičius Manager of the Investment Company mantas.auruskevicius@lordslb.lt

Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production. This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales. “Our team continues to deliver on...

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:10 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.    About Generation Bio    Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate...

Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTA Increased tumor retention and total tumor uptake anticipated by using optimized universal Radiohapten Company plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, “Proteus”, in 1H 2026 with data readout in 2H 2026; Part B of Trial 1001 anticipated to initiate with Proteus in 1H 2027 with data readout in 2H 2027 Expanded Radiopharmaceutical pipeline to focus on target franchise areas in oncology, with specific programs that maximize pretargeting approach in high-value commercial targets Company to host virtual Radiopharmaceutical R&D update today at...

LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that its wholly owned subsidiary, Ault Capital Group, Inc. (“ACG”) intends to purchase up to $10 million in XRP, the digital asset developed by Ripple Labs and native to the XRP Ledger, by the end of 2025. The XRP, when purchased, will be deemed a crypto asset and held on the Company’s balance sheet at fair value with changes recognized in operating expenses on the consolidated statements of operations. This strategic move is designed to support the Company’s broader expansion into financial services through ACG. “ACG plans to expand its financial services division and broaden the services it offers beyond lending, including cryptocurrency-based products on a...

–Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone– –Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program– —Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone– —Enobosarm 3mg added to semaglutide resulted in the highly selective loss of fat mass, accounting for 99% of the total weight lost, while preserving lean mass— –With this positive Phase 2b QUALITY study, Veru has requested an End of Phase 2 meeting with FDA to provide regulatory clarity on the Phase 3 clinical program– –The...

BEIJING, May 28, 2025 (GLOBE NEWSWIRE) — JD.com, Inc. (“JD.com” or the “Company”) (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter)), a leading supply chain-based technology and service provider, today announced that it will hold its annual general meeting of shareholders (the “AGM”) at Building A, No. 18 Kechuang 11 Street, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing 101111, People’s Republic of China, on June 20, 2025 at 3:00 p.m. (Hong Kong time). No proposal will be submitted for shareholder approval at the AGM. Instead, the AGM will serve as an open forum for shareholders of record to discuss Company affairs with management. Holders of record of Class A ordinary shares and Class B ordinary shares of the Company at the close of business on May 27, 2025 (Hong Kong time) are entitled...